DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

Altre lingue Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Azioni

688192

CNE1000055W8

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 06/05/2024			Variaz. 5gg	Var. 1 gen.
45,93 ^CNY	+1,95%		+1,66%	-4,01%

29/04	Dizal (Jiangsu) Pharmaceutical Co., Ltd. riporta i risultati degli utili per il primo trimestre terminato il 31 marzo 2024	CI
24/04	Dizal (Jiangsu) Pharmaceutical Co., Ltd. annuncia due abstract che presentano i dati più recenti su Sunvozertinib nel tumore al polmone non a piccole cellule	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer	24/04
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	07/04
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine	13/12
Dizal Pharmaceutical Co., Ltd.(SHSE:688192) added to Shanghai Stock Exchange Health Care Sector Index	11/12
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH	10/12
Dizal Pharma to Invest 700 Million Yuan in New Dermatology Venture	22/11
Dizal Pharma Presents Positive Results of Lung Cancer Drug	24/10/23
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients	23/10/23
Chinese Drug Regulator Puts Dizal Pharma's Lymphoma Drug in Priority Review	22/09/23
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL	21/09/23
Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index	18/09/23
Dizal Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL	14/09/23
Dizal (Jiangsu) Pharmaceutical's Anti-Lymphoma Medication Research Results Published in European Oncology Journal	11/09/23
Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology	10/09/23
Anova Enterprises, Inc. Partners with Dizal Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 Insertion Mutation	06/09/23
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23
Dizal's Sunvozertinib Approves by China NMPA with Potential for Best-In-Class Therapy in NSCLC with EGFR Exon20ins Mutations	23/08/23
Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA	17/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Azioni

688192

CNE1000055W8

Altre lingue

Filtri